HONG KONG, SHANGHAI and FLORHAM PARK, N.J. — September 29, 2026
HUTCHMED (China) Limited announced that AstraZeneca has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of ORPATHYS® (savolitinib) in combination with TAGRISSO® (osimertinib) for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have MET overexpression or amplification and whose disease has progressed following EGFR tyrosine kinase inhibitor (TKI) therapy. The application is supported by the global Phase 3 SAFFRON trial, which reported statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS) compared with doublet platinum-based chemotherapy in patients who progressed following TAGRISSO treatment. The combination is designed as a biomarker-directed, all-oral treatment approach for EGFR-mutated NSCLC with MET-driven resistance.
SAFFRON Provides Phase 3 Evidence for MET-Driven Progression
The SAFFRON Phase 3 trial enrolled 338 patients with EGFR-mutated, locally advanced or metastatic NSCLC with MET overexpression or amplification after progression on first- or second-line TAGRISSO. The randomized, open-label, multicenter global study evaluated ORPATHYS 300 mg twice daily plus TAGRISSO 80 mg once daily against doublet platinum-based chemotherapy. PFS was the primary endpoint, while OS was a key secondary endpoint. HUTCHMED reported that the combination produced statistically significant and clinically meaningful improvements in both measures, with the safety profile consistent with the known profiles of the individual medicines and no new safety concerns reported. The SAFFRON results build on findings from the Phase 3 SACHI trial and Phase 2 SAVANNAH study, which supported the development of MET-directed treatment in EGFR-mutated NSCLC following EGFR-TKI progression. Detailed SAFFRON results are scheduled for presentation in a Presidential Symposium at ESMO Congress 2026.
MET Alterations Represent a Resistance Mechanism in EGFR NSCLC
MET overexpression or amplification is an established mechanism of resistance to third-generation EGFR-TKI therapy, creating an important treatment challenge for patients whose tumors progress while receiving medicines such as osimertinib. HUTCHMED estimates that approximately 34% of tumors may develop high levels of MET overexpression or amplification following progression on a third-generation EGFR TKI. The SAFFRON study prospectively selected patients using high MET thresholds identified in the SAVANNAH Phase 2 trial, with MET status assessed through immunohistochemistry and fluorescence in situ hybridization. ORPATHYS is an oral, selective MET tyrosine kinase inhibitor designed to inhibit MET pathway activation associated with gene amplification, protein overexpression and certain MET alterations. The combination with TAGRISSO is intended to simultaneously address EGFR signaling and MET-driven resistance in biomarker-selected patients.
ORPATHYS-TAGRISSO Combination Builds Global Regulatory Path
The U.S. NDA submission expands the regulatory development of the ORPATHYS-TAGRISSO combination beyond China, where the combination has already been approved for patients with locally advanced or metastatic EGFR mutation-positive nonsquamous NSCLC with MET amplification after progression on EGFR-TKI therapy, based on SACHI Phase 3 data. ORPATHYS is also approved in China for NSCLC with MET exon 14 skipping alterations and has a conditional approval for MET-amplified gastric or gastroesophageal junction adenocarcinoma after at least two prior systemic treatments. The combination has additionally received temporary authorization in Switzerland for EGFR-mutated NSCLC with high MET overexpression or amplification following TAGRISSO progression, based on SAVANNAH data. HUTCHMED and AstraZeneca are jointly developing ORPATHYS, with AstraZeneca responsible for commercialization. The U.S. regulatory filing now places the SAFFRON-supported regimen under FDA review for this biomarker-defined population.
Source :HUTCHMED, press release



